EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses

Yaohui Wang, Dongxing Wang, Houming Zhao, Yanming Zhou, Qiyang Liang, Qingbo Huang, Cheng Peng, Junnan Xu, Gang Guo, Guoqiang Yang, Luyao Chen, Yang Xun und 4 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2026-015686 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yaohui Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Urology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with very-high risk clear cell renal cell carcinoma (ccRCC) remain at substantial risk of recurrence after nephrectomy. However, heterogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospective data in this population, warrants further investigation.

Methods

This multicenter, prospective, non-randomized, controlled phase II trial enrolled patients with very-high risk ccRCC following nephrectomy. Patients received either adjuvant penpulimab or routine surveillance, with 1:1 propensity score matching (PSM) applied to balance baseline characteristics. The primary endpoint was disease-free survival (DFS), with secondary endpoints including overall survival (OS) and safety. Plasma proteomic and metabolomic profiling was conducted for exploratory analyses.

Results

Given the non-randomized design, baseline imbalances were addressed by PSM, yielding well-balanced cohorts of 87 patients per group. Adjuvant penpulimab was associated with improved DFS compared with surveillance (HR, 0.37; 95% CI 0.16 to 0.89; p=0.026), whereas OS data remained immature. Consistent with Kaplan-Meier estimates, 1-year (94.25% vs 80.46%) and 2-year (88.68% vs 75.38%) DFS rates favored the penpulimab group (log-rank p=0.026). Penpulimab was generally well tolerated, with most treatment-related adverse events being grade 1–2. Plasma proteomic and metabolomic analyses revealed enrichment of immune response-related pathways in patients without disease progression, with circulating biomarkers associated with DFS.

Conclusions

Adjuvant penpulimab was associated with improved DFS and a manageable safety profile in patients with very-high risk ccRCC. Plasma-based biomarkers associated with disease progression may inform postoperative risk stratification and warrant further validation. Trial registration number ChiCTR2200062189.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntibodies, Monoclonal, HumanizedHumansProspective StudiesFemaleMultiomicsMaleAgedMiddle AgedProteomicsChemotherapy, AdjuvantBiomarkers, TumorMetabolomics

Stichwörter der Autor:innen

BiomarkerImmune Checkpoint InhibitorKidney Cancer

Substanzen

Antibodies, Monoclonal, HumanizedBiomarkers, Tumorpenpulimab

Autor:innen und Institutionen

  • Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.
  • Medical School of Chinese PLA, Beijing, China.
  • Department of Urology, 940th Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou, Gansu, China.
  • Department of Urology, Medical School of Chinese PLA, Beijing, China.
  • Department of Urology, The First Affiliated Hospital of Jiangxi Medical College, Nanchang, Jiangxi, China.
  • Department of Urology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, Hubei, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Wang, D., Zhao, H., Zhou, Y., Liang, Q., Huang, Q., Peng, C., Xu, J., Guo, G., Yang, G., Chen, L., Xun, Y., Du, J., Ma, X., Zhang, X., & Gu, L. (2026). Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-015686

Vancouver

Wang Y, Wang D, Zhao H, Zhou Y, Liang Q, Huang Q, et al. Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-015686

BibTeX
@article{Wang2026,
  author = {Wang, Yaohui and Wang, Dongxing and Zhao, Houming and Zhou, Yanming and Liang, Qiyang and Huang, Qingbo and Peng, Cheng and Xu, Junnan and Guo, Gang and Yang, Guoqiang and Chen, Luyao and Xun, Yang and Du, Jun and Ma, Xin and Zhang, Xu and Gu, Liangyou},
  title = {Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2026-015686}
}
Kostenlos starten →